iSpecimen Inc. Files S-1 Registration Statement
Ticker: ISPC · Form: S-1 · Filed: Oct 18, 2024 · CIK: 1558569
Sentiment: neutral
Topics: s-1, registration-statement, sec-filing
TL;DR
iSpecimen filed an S-1, looks like they're raising capital soon.
AI Summary
iSpecimen Inc. filed an S-1 registration statement on October 18, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices at 8 Cabot Road, Suite 1800, Woburn, MA, operates in the commercial physical & biological research sector. Tracy Curley is listed as the Chief Executive Officer.
Why It Matters
This S-1 filing indicates iSpecimen Inc. is preparing to offer new securities to the public, which could impact its capital structure and future growth prospects.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with new public offerings, which carry inherent market and execution risks.
Key Numbers
- 333-282736 — SEC File Number (Identifies the specific SEC registration)
- 241381520 — Film Number (Internal SEC processing number)
Key Players & Entities
- iSpecimen Inc. (company) — Registrant
- October 18, 2024 (date) — Filing Date
- Securities Act of 1933 (legal_document) — Governing Act
- Delaware (jurisdiction) — State of Incorporation
- 8 Cabot Road, Suite 1800, Woburn, MA 01801 (address) — Principal Executive Offices
- Tracy Curley (person) — Chief Executive Officer
FAQ
What is the purpose of this S-1 filing for iSpecimen Inc.?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating iSpecimen Inc.'s intent to offer securities to the public.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the Securities and Exchange Commission on October 18, 2024.
Who is the Chief Executive Officer of iSpecimen Inc.?
Tracy Curley is the Chief Executive Officer of iSpecimen Inc.
In which state was iSpecimen Inc. incorporated?
iSpecimen Inc. was incorporated in Delaware.
What is the primary business sector for iSpecimen Inc. according to the filing?
iSpecimen Inc. is classified under the SIC code 8731, which corresponds to SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 4,476 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-10-18 17:25:39
Key Financial Figures
- $0.0001 — 5 shares of our common stock, par value $0.0001 per share (the "Shares") at an assumed
- $4.11 — at an assumed public offering price of $4.11 per share, which was the reported closi
- $0 — be equal to the price per Share, minus $0.0001, and the remaining exercise price
Filing Documents
- tm2425676-1_s1.htm (S-1) — 940KB
- tm2425676d2_ex1-1.htm (EX-1.1) — 92KB
- tm2425676d2_ex4-4.htm (EX-4.4) — 98KB
- tm2425676d2_ex5-1.htm (EX-5.1) — 15KB
- tm2425676d2_ex10-46.htm (EX-10.46) — 182KB
- tm2425676d2_ex10-47.htm (EX-10.47) — 36KB
- tm2425676d2_ex23-1.htm (EX-23.1) — 2KB
- tm2425676d2_ex-filingfees.htm (EX-FILING FEES) — 27KB
- lg_ispecimen-4c.jpg (GRAPHIC) — 14KB
- tm2425676d2_ex10-47img001.jpg (GRAPHIC) — 13KB
- tm2425676d2_ex5-1img01.jpg (GRAPHIC) — 7KB
- 0001104659-24-109912.txt ( ) — 1442KB
RISK FACTORS
RISK FACTORS 16 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 42
USE OF PROCEEDS
USE OF PROCEEDS 43 CAPITALIZATION 44 MANAGEMENT 46 DESCRIPTION OF OUR SECURITIES 52 PLAN OF DISTRIBUTION 57 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 60 LEGAL MATTERS 65 EXPERTS 65 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 65 WHERE YOU CAN FIND MORE INFORMATION 66 This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See "Risk Factors" and "Special Note Regarding Forward-Looking Statements." i TABLE OF CONTENTS ABOUT THIS PROSPECTUS The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such